Skip to Content

Ciprofloxacin / hydrocortisone otic Pregnancy and Breastfeeding Warnings

Ciprofloxacin / hydrocortisone otic is also known as: Cipro HC

Ciprofloxacin / hydrocortisone otic Pregnancy Warnings

Ciprofloxacin-hydrocortisone otic has been assigned to pregnancy category C by the FDA. Animal studies have failed to reveal embryotoxicity or teratogenicity, although maternal toxicity in some animal studies resulted in increased incidence of abortion. There are no controlled data in human pregnancy. Systemic ciprofloxacin has been shown to distribute into amniotic fluid. Concentrations reported were 57% (at 2 to 4 hours post dose) to 1000% (at 10 to 12 hours post dose) of that found in maternal serum. Cartilage damage and arthropathies associated with ciprofloxacin have been reported in immature animals of various species, giving rise to concern over its possible toxic effects on human fetal bone formation. Animal studies have shown corticosteroids to be teratogenic in mice and rabbits following multiple dose topical application. However, limited data indicate that systemic absorption after otic administration of ciprofloxacin-hydrocortisone is extremely low. Ciprofloxacin-hydrocortisone otic should only be given during pregnancy when benefit outweighs risk.

See references

Ciprofloxacin / hydrocortisone otic Breastfeeding Warnings

There are no data on the excretion of ciprofloxacin-hydrocortisone otic into human milk. Concentrations of orally administered ciprofloxacin found in breast milk have ranged from 85% (at 24 hours post dose) to 214% (at 4 hours post dose) of maternal serum concentration. In one case report, an infant developed perforated pseudomembranous colitis following ingestion of ciprofloxacin via the mother's milk. In addition, quinolone-induced cartilage erosion and arthropathies that have been observed in juvenile animals render some concern over its possible toxic effects on the developing joints of nursing infants. However, limited data indicate that systemic absorption after otic administration is extremely low. Plasma levels of ciprofloxacin and hydrocortisone are expected to be below the level of quantitation after administration of 3 drops of suspension into the ear. The manufacturer recommends that due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue the drug or to discontinue nursing, taking into account the importance of the drug to the mother.

See references

References for pregnancy information

  1. "Product Information. Cipro HC Otic (ciprofloxacin-hydrocortisone otic)." Bayer, West Haven, CT.

References for breastfeeding information

  1. "Product Information. Cipro HC Otic (ciprofloxacin-hydrocortisone otic)." Bayer, West Haven, CT.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.